Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board

Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board

January 21, 2015

CAMBRIDGE, Mass., Jan. 21, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, announced today the addition of Mark Wilcox, M.D., of the University of Leeds, to its Scientific Advisory Board (SAB).

Avedro Appoints Brian Roberts as Chief Financial Officer

Avedro Appoints Brian Roberts as Chief Financial Officer

January 20, 2015

 WALTHAM, Mass.--()--Avedro Inc., a Boston-based ophthalmic pharmaceutical and medical device company announced today that Brian K. Roberts is joining the company as its new Chief Financial Officer. In this position, Mr.

Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections

Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections

January 13, 2015

Paper Co-Authored by T2 Biosystems' Co-Founders Dr. Robert Langer and Dr. Ralph Weissleder Underscores Potential for T2MR Over Existing Diagnostic Methodologies

Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer

Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer

January 15, 2015

CAMBRIDGE, Mass., Jan.15, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, today announced the appointment of Michele (Shelley) Trucksis, Ph.D., M.D., as Executive Vice President and Chief Medical Officer. In this role, Dr. Trucksis will be responsible for overseeing the clinical development and operations of Seres' Ecobiotic® product pipeline.

Oasys Water’s Global Momentum Continues with Asia-Pacific Expansion and Deployment of its Forward Osmosis Systems

Oasys Water’s Global Momentum Continues with Asia-Pacific Expansion and Deployment of its Forward Osmosis Systems

January 13, 2015

 Water Treatment and Desalination Innovator Completes First Commercial Year Expanding its International Reach

Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

January 13, 2015

 CAMBRIDGE, Mass., January 13, 2015 – Moderna Therapeutics today announced a license and collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna is a pioneer in the development of mRNA Therapeutics™ across a range of therapeutic applications.

Pivotal Data for T2Candida and T2Dx Published in Clinical Infectious Diseases

Pivotal Data for T2Candida and T2Dx Published in Clinical Infectious Diseases

January 13, 2015

– Study Demonstrated 91.1% Sensitivity and Specificity of 99.4% for Sepsis Pathogen Detection in 3-5 Hours Without the Need for Blood Culture –

– Results From First Large, Multicenter Clinical Trial Demonstrate Breakthrough Potential of T2MR Technology –

Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration

Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration

January 12, 2015

AG-120 would be the second investigational medicine licensed by Celgene and demonstrates strength and progress of cancer metabolism collaboration

Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering

Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering

January 12, 2015

Poster Presented at Keystone Symposium for Precision Genome Engineering and Synthetic Biology

Acceleron Pharma Outlines Corporate Objectives for 2015

Acceleron Pharma Outlines Corporate Objectives for 2015

January 12, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its major corporate research and development objectives for 2015. Acceleron has four internally discovered and developed investigational protein therapeutics in human clinical trials and expects all four molecules to be in either phase 2 or phase 3 clinical trials by the end of 2015.